AMRN – Amarin Corp ADR

Float Short %

1.99

Margin Of Safety %

Put/Call OI Ratio

0.09

EPS Next Q Diff

EPS Last/This Y

4.22

EPS This/Next Y

0.37

Price

16.58

Target Price

Analyst Recom

Performance Q

-17.2

Relative Volume

1.29

Beta

0.84

Ticker: AMRN

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	AMRN	14.23	0.04	0.00	4360
2025-12-29	AMRN	14.04	0.04	0.00	5264
2025-12-30	AMRN	13.52	0.04	0.73	5526
2025-12-31	AMRN	14.01	0.04	0.28	5536
2026-01-02	AMRN	13.65	0.04	0.19	5551
2026-01-05	AMRN	13.51	0.04	0.37	5600
2026-01-06	AMRN	13.73	0.04	0.20	5709
2026-01-07	AMRN	14.08	0.04	0.21	5814
2026-01-08	AMRN	16.4	0.04	0.08	5853
2026-01-09	AMRN	15.82	0.04	0.04	6290
2026-01-12	AMRN	15.52	0.04	0.51	6520
2026-01-13	AMRN	15.17	0.05	0.11	6610
2026-01-14	AMRN	15.04	0.05	2.55	6642
2026-01-15	AMRN	14.99	0.06	0.05	6720
2026-01-16	AMRN	14.71	0.06	0.00	6749
2026-01-20	AMRN	15.67	0.09	0.04	2815
2026-01-21	AMRN	15.25	0.08	0.29	3225
2026-01-22	AMRN	16.6	0.09	0.12	3270
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	AMRN	14.23	117.5	-	0.22
2025-12-29	AMRN	14.09	117.5	-	0.22
2025-12-30	AMRN	13.56	117.5	-	0.22
2025-12-31	AMRN	13.98	117.5	-	0.22
2026-01-02	AMRN	13.67	117.5	-	0.22
2026-01-05	AMRN	13.51	117.5	-	0.22
2026-01-06	AMRN	13.75	117.5	-	0.22
2026-01-07	AMRN	14.00	117.5	-	0.22
2026-01-08	AMRN	16.41	117.5	-	0.22
2026-01-09	AMRN	15.78	117.5	-	0.22
2026-01-12	AMRN	15.53	117.5	-	0.22
2026-01-13	AMRN	15.18	117.5	-	0.22
2026-01-14	AMRN	15.02	117.5	-	0.22
2026-01-15	AMRN	14.95	117.5	-	0.22
2026-01-16	AMRN	14.80	117.5	-	0.22
2026-01-20	AMRN	15.58	117.5	-	0.22
2026-01-21	AMRN	15.25	117.5	-	0.22
2026-01-22	AMRN	16.58	117.5	-	0.22
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	AMRN	0.00	3.14	1.96
2025-12-29	AMRN	0.00	3.14	1.96
2025-12-30	AMRN	0.00	3.14	1.96
2025-12-31	AMRN	0.00	3.14	1.96
2026-01-02	AMRN	0.00	3.14	1.96
2026-01-05	AMRN	0.00	3.15	1.96
2026-01-06	AMRN	0.00	3.15	1.96
2026-01-07	AMRN	0.00	3.15	1.96
2026-01-08	AMRN	0.00	3.15	1.96
2026-01-09	AMRN	0.00	3.15	1.96
2026-01-12	AMRN	0.00	3.16	1.96
2026-01-13	AMRN	0.00	3.16	1.99
2026-01-14	AMRN	0.00	3.16	1.99
2026-01-15	AMRN	0.00	3.16	1.99
2026-01-16	AMRN	0.00	3.16	1.99
2026-01-20	AMRN	0.00	2.99	1.99
2026-01-21	AMRN	0.00	2.99	1.99
2026-01-22	AMRN	0.00	2.99	1.99
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.07

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

2.99

Beta

0.84

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-95.5

Target Price

P/E

Forward P/E

115.38

PEG

1.5

P/S

1.51

P/B

0.75

P/Free Cash Flow

EPS

-4.17

Average EPS Est. Cur. Y

0.22

EPS Next Y. (Est.)

0.59

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-37.87

Relative Volume

1.29

Return on Equity vs Sector %

-46

Return on Equity vs Industry %

-55.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

Amarin Corporation plc

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 275

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

stock quote shares AMRN – Amarin Corp ADR Stock Price stock today

news today AMRN – Amarin Corp ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch AMRN – Amarin Corp ADR yahoo finance google finance

stock history AMRN – Amarin Corp ADR invest stock market

stock prices AMRN premarket after hours

ticker AMRN fair value insiders trading

GRFS – Grifols, S.A.

Float Short %

2.59

Margin Of Safety %

Put/Call OI Ratio

0.25

EPS Next Q Diff

EPS Last/This Y

0.74

EPS This/Next Y

0.19

Price

9.1

Target Price

12.57

Analyst Recom

1.67

Performance Q

-2.46

Relative Volume

0.47

Beta

0.66

Ticker: GRFS

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	GRFS	9.09	0.21	4.67	1757
2025-12-29	GRFS	9.11	0.23	0.00	1786
2025-12-30	GRFS	9.22	0.23	0.00	1786
2025-12-31	GRFS	9.35	0.23	0.00	1786
2026-01-02	GRFS	9.25	0.22	0.08	1808
2026-01-05	GRFS	9.31	0.22	0.00	1831
2026-01-06	GRFS	9.19	0.22	0.55	1831
2026-01-07	GRFS	9.47	0.23	0.00	1862
2026-01-08	GRFS	9.49	0.23	999.99	1859
2026-01-09	GRFS	9.38	0.23	0.20	1861
2026-01-12	GRFS	9.14	0.23	0.40	1859
2026-01-13	GRFS	8.83	0.23	1.60	1866
2026-01-14	GRFS	9.24	0.25	0.00	1918
2026-01-15	GRFS	8.96	0.24	5.00	1947
2026-01-16	GRFS	8.9	0.25	0.52	1952
2026-01-20	GRFS	8.65	0.25	0.00	1914
2026-01-21	GRFS	9.01	0.24	1.58	1997
2026-01-22	GRFS	9.11	0.25	0.00	2027
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	GRFS	9.08	-	-	1.01
2025-12-29	GRFS	9.12	-	-	1.01
2025-12-30	GRFS	9.21	-	-	1.01
2025-12-31	GRFS	9.35	-	-	1.01
2026-01-02	GRFS	9.26	-	-	1.01
2026-01-05	GRFS	9.31	-	-	1.01
2026-01-06	GRFS	9.19	-	-	1.01
2026-01-07	GRFS	9.48	-	-	1.01
2026-01-08	GRFS	9.49	-	-	1.01
2026-01-09	GRFS	9.38	-	-	1.01
2026-01-12	GRFS	9.15	-	-	1.01
2026-01-13	GRFS	8.83	-	-	1.01
2026-01-14	GRFS	9.24	-	-	1.01
2026-01-15	GRFS	8.94	-	-	1.01
2026-01-16	GRFS	8.89	-	-	1.01
2026-01-20	GRFS	8.64	-	-	1.01
2026-01-21	GRFS	9.02	-	-	1.01
2026-01-22	GRFS	9.10	-	-	1.01
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	GRFS	0.00	1.41	2.58
2025-12-29	GRFS	0.00	1.48	2.58
2025-12-30	GRFS	0.00	1.48	2.58
2025-12-31	GRFS	0.00	1.48	2.58
2026-01-02	GRFS	0.00	1.48	2.58
2026-01-05	GRFS	0.00	1.47	2.58
2026-01-06	GRFS	0.00	1.47	2.58
2026-01-07	GRFS	0.00	1.47	2.58
2026-01-08	GRFS	0.00	1.47	2.58
2026-01-09	GRFS	0.00	1.47	2.58
2026-01-12	GRFS	0.00	1.48	2.58
2026-01-13	GRFS	0.00	1.48	2.59
2026-01-14	GRFS	0.00	1.48	2.59
2026-01-15	GRFS	0.00	1.48	2.59
2026-01-16	GRFS	0.00	1.48	2.59
2026-01-20	GRFS	0.00	1.13	2.59
2026-01-21	GRFS	0.00	1.13	2.59
2026-01-22	GRFS	0.00	1.13	2.59
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.29

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

1.13

Beta

0.66

Average Sales Estimate Current Quarter

1904

Average Sales Estimate Next Quarter

Fair Value

12.37

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-70.9

Target Price

12.57

P/E

14.83

Forward P/E

8.7

PEG

0.38

P/S

0.28

P/B

1.02

P/Free Cash Flow

2.48

EPS

0.61

Average EPS Est. Cur. Y

1.01

EPS Next Y. (Est.)

1.2

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

5.02

Relative Volume

0.47

Return on Equity vs Sector %

-20

Return on Equity vs Industry %

-29.5

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.14

EBIT Estimation

Grifols, S.A.

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 23800

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.

stock quote shares GRFS – Grifols, S.A. Stock Price stock today

news today GRFS – Grifols, S.A. stock forecast ,stock prediction 2023 2024 2025

marketwatch GRFS – Grifols, S.A. yahoo finance google finance

stock history GRFS – Grifols, S.A. invest stock market

stock prices GRFS premarket after hours

ticker GRFS fair value insiders trading

SNY – Sanofi

Float Short %

0.32

Margin Of Safety %

Put/Call OI Ratio

1.3

EPS Next Q Diff

-0.68

EPS Last/This Y

1.96

EPS This/Next Y

0.33

Price

46.53

Target Price

56.65

Analyst Recom

1.83

Performance Q

-6.36

Relative Volume

0.95

Beta

0.44

Ticker: SNY

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	SNY	48.47	1.86	0.26	78906
2025-12-29	SNY	48.37	1.86	94.15	78991
2025-12-30	SNY	48.76	1.81	1.19	77736
2025-12-31	SNY	48.48	1.81	3.08	78350
2026-01-02	SNY	48.05	1.81	2.27	78449
2026-01-05	SNY	47.51	1.81	1.04	78544
2026-01-06	SNY	48.17	1.80	0.06	79053
2026-01-07	SNY	48.38	1.71	0.24	80871
2026-01-08	SNY	48.12	1.49	0.03	85663
2026-01-09	SNY	49.02	1.41	0.12	87824
2026-01-12	SNY	47.6	1.39	0.08	88475
2026-01-13	SNY	47.2	1.51	0.82	85792
2026-01-14	SNY	47.94	1.50	0.17	86024
2026-01-15	SNY	47.47	1.41	2.50	88446
2026-01-16	SNY	46.6	1.33	0.36	85769
2026-01-20	SNY	45.73	1.41	2.08	38461
2026-01-21	SNY	46.19	1.37	0.42	39777
2026-01-22	SNY	46.53	1.30	0.44	41014
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	SNY	48.48	18.3	3933.4	4.56
2025-12-29	SNY	48.37	18.3	3932.7	4.56
2025-12-30	SNY	48.75	18.3	4008.1	4.56
2025-12-31	SNY	48.49	18.3	3725.6	4.56
2026-01-02	SNY	48.20	18.3	3692.8	4.56
2026-01-05	SNY	47.51	18.3	3684.6	4.56
2026-01-06	SNY	48.17	18.3	3973.3	4.56
2026-01-07	SNY	48.37	18.3	3988.4	4.56
2026-01-08	SNY	48.10	18.3	3674.9	4.56
2026-01-09	SNY	49.00	18.3	3934.1	4.56
2026-01-12	SNY	47.60	18.3	3337.3	4.56
2026-01-13	SNY	47.19	18.3	3531.7	4.56
2026-01-14	SNY	47.90	18.3	4019.5	4.56
2026-01-15	SNY	47.47	18.3	3582.9	4.56
2026-01-16	SNY	46.61	24.3	3603.0	4.56
2026-01-20	SNY	45.76	24.6	3503.0	4.56
2026-01-21	SNY	46.16	24.6	4052.6	4.56
2026-01-22	SNY	46.53	24.6	3839.7	4.56
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	SNY	0	-0.88	0.31
2025-12-29	SNY	0	-0.86	0.31
2025-12-30	SNY	0	-0.86	0.31
2025-12-31	SNY	0	-0.86	0.31
2026-01-02	SNY	0	-0.86	0.31
2026-01-05	SNY	0	1.25	0.31
2026-01-06	SNY	0	1.25	0.31
2026-01-07	SNY	0	1.25	0.31
2026-01-08	SNY	0	1.25	0.31
2026-01-09	SNY	0	1.25	0.31
2026-01-12	SNY	0	1.16	0.31
2026-01-13	SNY	0	1.16	0.32
2026-01-14	SNY	0	1.16	0.32
2026-01-15	SNY	0	1.16	0.32
2026-01-16	SNY	0	1.16	0.32
2026-01-20	SNY	0	2.56	0.32
2026-01-21	SNY	0	2.56	0.32
2026-01-22	SNY	0	2.56	0.32
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

1.7

Avg. EPS Est. Current Quarter

0.81

Avg. EPS Est. Next Quarter

1.02

Insider Transactions

Institutional Transactions

2.56

Beta

0.44

Average Sales Estimate Current Quarter

11159

Average Sales Estimate Next Quarter

9919

Fair Value

65.15

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

22.6

Max Drawdown 5-Year %

-33.5

Target Price

56.65

P/E

11.61

Forward P/E

9.45

PEG

0.78

P/S

2.6

P/B

1.38

P/Free Cash Flow

10.42

EPS

4.01

Average EPS Est. Cur. Y

4.56

EPS Next Y. (Est.)

4.89

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

22.98

Relative Volume

0.95

Return on Equity vs Sector %

-20.9

Return on Equity vs Industry %

-30.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.05

EBIT Estimation

3839.7

Sanofi

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 82878

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

stock quote shares SNY – Sanofi Stock Price stock today

news today SNY – Sanofi stock forecast ,stock prediction 2023 2024 2025

marketwatch SNY – Sanofi yahoo finance google finance

stock history SNY – Sanofi invest stock market

stock prices SNY premarket after hours

ticker SNY fair value insiders trading

NVO – Novo Nordisk A/S

Float Short %

0.96

Margin Of Safety %

-14

Put/Call OI Ratio

0.85

EPS Next Q Diff

4.06

EPS Last/This Y

19.47

EPS This/Next Y

-0.37

Price

62.22

Target Price

61.54

Analyst Recom

2.27

Performance Q

13.6

Relative Volume

1.02

Beta

0.65

Ticker: NVO

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	NVO	52.39	0.72	0.29	1526521
2025-12-29	NVO	51.46	0.73	0.39	1454651
2025-12-30	NVO	51.24	0.73	0.42	1466616
2025-12-31	NVO	50.88	0.73	0.72	1476410
2026-01-02	NVO	52.4	0.74	0.39	1500952
2026-01-05	NVO	55.11	0.74	0.30	1457051
2026-01-06	NVO	56.19	0.74	0.39	1479901
2026-01-07	NVO	56.5	0.75	0.78	1507749
2026-01-08	NVO	57.36	0.77	1.22	1543044
2026-01-09	NVO	58.83	0.81	0.82	1593862
2026-01-12	NVO	59.85	0.81	0.75	1554726
2026-01-13	NVO	59.56	0.79	0.47	1560931
2026-01-14	NVO	58.9	0.79	0.43	1585092
2026-01-15	NVO	57.12	0.80	1.15	1606497
2026-01-16	NVO	62.32	0.84	0.42	1693378
2026-01-20	NVO	60.72	0.88	0.60	1328034
2026-01-21	NVO	59.32	0.84	0.64	1361008
2026-01-22	NVO	62.23	0.85	0.59	1422546
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	NVO	52.41	-8.3	-1962.7	23.03
2025-12-29	NVO	51.45	-8.3	-2275.2	23.03
2025-12-30	NVO	51.20	-8.3	-1787.9	23.03
2025-12-31	NVO	50.88	-8.3	-1888.4	23.03
2026-01-02	NVO	52.40	-8.3	-1383.6	23.03
2026-01-05	NVO	55.13	-8.3	-676.6	23.03
2026-01-06	NVO	56.23	-8.3	-1661.6	23.03
2026-01-07	NVO	56.56	-8.3	-1547.5	23.03
2026-01-08	NVO	57.35	-8.3	-2338.5	23.03
2026-01-09	NVO	58.83	-8.3	-1932.7	23.03
2026-01-12	NVO	59.85	-8.3	-2170.1	23.03
2026-01-13	NVO	59.63	-8.3	-2122.6	23.03
2026-01-14	NVO	58.92	-8.3	-2556.0	23.03
2026-01-15	NVO	57.12	-8.3	-2882.1	23.03
2026-01-16	NVO	62.35	-8.3	-497.6	23.03
2026-01-20	NVO	60.67	-7.9	-2278.8	23.03
2026-01-21	NVO	59.33	-7.9	-2725.3	23.03
2026-01-22	NVO	62.22	-7.9	-1016.4	23.03
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	NVO	0	-1.39	0.85
2025-12-29	NVO	0	-1.53	0.85
2025-12-30	NVO	0	-1.53	0.85
2025-12-31	NVO	0	-1.53	0.85
2026-01-02	NVO	0	-1.53	0.85
2026-01-05	NVO	0	-1.32	0.85
2026-01-06	NVO	0	-1.32	0.85
2026-01-07	NVO	0	-1.32	0.85
2026-01-08	NVO	0	-1.32	0.85
2026-01-09	NVO	0	-1.32	0.85
2026-01-12	NVO	0	-1.33	0.85
2026-01-13	NVO	0	-1.33	0.96
2026-01-14	NVO	0	-1.33	0.96
2026-01-15	NVO	0	-1.33	0.96
2026-01-16	NVO	0	-1.33	0.96
2026-01-20	NVO	0	-1.66	0.96
2026-01-21	NVO	0	-1.66	0.96
2026-01-22	NVO	0	-1.66	0.96
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

1.02

Avg. EPS Est. Current Quarter

5.82

Avg. EPS Est. Next Quarter

5.08

Insider Transactions

Institutional Transactions

-1.66

Beta

0.65

Average Sales Estimate Current Quarter

77280

Average Sales Estimate Next Quarter

70302

Fair Value

53.34

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-68.5

Target Price

61.54

P/E

18.13

Forward P/E

18.02

PEG

3.61

P/S

4.49

P/B

10.34

P/Free Cash Flow

20.96

EPS

3.43

Average EPS Est. Cur. Y

23.03

EPS Next Y. (Est.)

22.66

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

32.76

Relative Volume

1.02

Return on Equity vs Sector %

33.8

Return on Equity vs Industry %

24.4

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.07

EBIT Estimation

-1016.4

Novo Nordisk A/S

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 78554

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

stock quote shares NVO – Novo Nordisk A/S Stock Price stock today

news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch NVO – Novo Nordisk A/S yahoo finance google finance

stock history NVO – Novo Nordisk A/S invest stock market

stock prices NVO premarket after hours

ticker NVO fair value insiders trading

OGN – Organon & Co.

Float Short %

6.78

Margin Of Safety %

Put/Call OI Ratio

0.81

EPS Next Q Diff

EPS Last/This Y

0.41

EPS This/Next Y

0.19

Price

9.74

Target Price

9.36

Analyst Recom

3.56

Performance Q

7.98

Relative Volume

0.8

Beta

0.53

Ticker: OGN

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	OGN	7.18	0.89	0.35	87348
2025-12-29	OGN	7.11	0.89	0.89	87494
2025-12-30	OGN	7.13	0.90	0.39	88133
2025-12-31	OGN	7.16	0.89	4.55	88769
2026-01-02	OGN	7.26	0.90	1.47	89722
2026-01-05	OGN	7.45	0.91	0.09	90931
2026-01-06	OGN	8.07	0.75	0.09	103841
2026-01-07	OGN	8.19	0.60	0.04	119329
2026-01-08	OGN	8.12	0.59	1.51	123195
2026-01-09	OGN	8.05	0.60	0.18	125425
2026-01-12	OGN	8.12	0.61	0.61	125676
2026-01-13	OGN	8.43	0.61	0.19	128268
2026-01-14	OGN	8.6	0.66	0.11	124547
2026-01-15	OGN	8.7	0.65	8.74	126760
2026-01-16	OGN	8.75	0.77	0.02	135719
2026-01-20	OGN	9.47	0.90	0.31	103472
2026-01-21	OGN	9.6	0.85	0.13	114170
2026-01-22	OGN	9.73	0.81	4.12	117656
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	OGN	7.18	-17.7	-	3.77
2025-12-29	OGN	7.11	-17.7	-	3.77
2025-12-30	OGN	7.14	-17.7	-	3.77
2025-12-31	OGN	7.16	-17.7	-	3.77
2026-01-02	OGN	7.26	-17.7	-	3.77
2026-01-05	OGN	7.45	-17.7	-	3.77
2026-01-06	OGN	8.07	-17.7	-	3.77
2026-01-07	OGN	8.19	-17.7	-	3.77
2026-01-08	OGN	8.13	-17.7	-	3.77
2026-01-09	OGN	8.04	-17.7	-	3.77
2026-01-12	OGN	8.13	-17.7	-	3.77
2026-01-13	OGN	8.43	-17.7	-	3.77
2026-01-14	OGN	8.60	-17.7	-	3.77
2026-01-15	OGN	8.71	-17.7	-	3.77
2026-01-16	OGN	8.75	-17.7	-	3.77
2026-01-20	OGN	9.47	-17.7	-	3.77
2026-01-21	OGN	9.60	-17.7	-	3.77
2026-01-22	OGN	9.74	-17.7	-	3.77
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	OGN	6.71	-4.95	6.41
2025-12-29	OGN	6.71	-4.62	6.41
2025-12-30	OGN	6.71	-4.62	6.41
2025-12-31	OGN	6.71	-4.62	6.41
2026-01-02	OGN	6.71	-4.62	6.41
2026-01-05	OGN	6.71	-4.01	6.41
2026-01-06	OGN	6.71	-4.01	6.41
2026-01-07	OGN	6.71	-4.01	6.41
2026-01-08	OGN	6.71	-4.01	6.41
2026-01-09	OGN	6.71	-4.01	6.41
2026-01-12	OGN	6.71	-4.47	6.41
2026-01-13	OGN	6.71	-4.47	6.78
2026-01-14	OGN	6.71	-4.47	6.78
2026-01-15	OGN	6.71	-4.47	6.78
2026-01-16	OGN	6.71	-4.47	6.78
2026-01-20	OGN	6.71	-4.10	6.78
2026-01-21	OGN	6.71	-4.10	6.78
2026-01-22	OGN	6.71	-4.10	6.78
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

1.01

Avg. EPS Est. Current Quarter

0.74

Avg. EPS Est. Next Quarter

1.01

Insider Transactions

6.71

Institutional Transactions

-4.1

Beta

0.53

Average Sales Estimate Current Quarter

1521

Average Sales Estimate Next Quarter

1515

Fair Value

11.23

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

75.3

Max Drawdown 5-Year %

Target Price

9.36

P/E

5.06

Forward P/E

2.48

PEG

P/S

0.4

P/B

2.79

P/Free Cash Flow

3.26

EPS

1.92

Average EPS Est. Cur. Y

3.77

EPS Next Y. (Est.)

3.96

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

7.95

Relative Volume

0.8

Return on Equity vs Sector %

28.1

Return on Equity vs Industry %

18.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.08

EBIT Estimation

Organon & Co.

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 10000

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

stock quote shares OGN – Organon & Co. Stock Price stock today

news today OGN – Organon & Co. stock forecast ,stock prediction 2023 2024 2025

marketwatch OGN – Organon & Co. yahoo finance google finance

stock history OGN – Organon & Co. invest stock market

stock prices OGN premarket after hours

ticker OGN fair value insiders trading

HZNP – Horizon Therapeutics Public Limited Company

Float Short %

3.11

Margin Of Safety %

-6

Put/Call OI Ratio

EPS Next Q Diff

0.02

EPS Last/This Y

EPS This/Next Y

0.18

Price

116.3

Target Price

116.5

Analyst Recom

Performance Q

13.24

Relative Volume

Beta

1.01

Ticker: HZNP

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	HZNP	116.3	N/A	N/A	0
2025-12-29	HZNP	116.3	N/A	N/A	0
2025-12-30	HZNP	116.3	N/A	N/A	0
2025-12-31	HZNP	116.3	N/A	N/A	0
2026-01-02	HZNP	116.3	N/A	N/A	0
2026-01-05	HZNP	116.3	N/A	N/A	0
2026-01-06	HZNP	116.3	N/A	N/A	0
2026-01-07	HZNP	116.3	N/A	N/A	0
2026-01-08	HZNP	116.3	N/A	N/A	0
2026-01-09	HZNP	116.3	N/A	N/A	0
2026-01-12	HZNP	116.3	N/A	N/A	0
2026-01-13	HZNP	116.3	N/A	N/A	0
2026-01-14	HZNP	116.3	N/A	N/A	0
2026-01-15	HZNP	116.3	N/A	N/A	0
2026-01-16	HZNP	116.3	N/A	N/A	0
2026-01-20	HZNP	116.3	N/A	N/A	0
2026-01-21	HZNP	116.3	N/A	N/A	0
2026-01-22	HZNP	116.3	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

Last Quarter Act. EPS

1.2

Avg. EPS Est. Current Quarter

1.22

Avg. EPS Est. Next Quarter

1.4

Insider Transactions

Institutional Transactions

1.83

Beta

1.01

Average Sales Estimate Current Quarter

954

Average Sales Estimate Next Quarter

1040

Fair Value

109.22

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

3.5

Max Drawdown 5-Year %

-50.9

Target Price

116.5

P/E

62.16

Forward P/E

18.11

PEG

12.43

P/S

7.31

P/B

5.01

P/Free Cash Flow

27.79

EPS

1.87

Average EPS Est. Cur. Y

4.64

EPS Next Y. (Est.)

5.66

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

12.02

Relative Volume

Return on Equity vs Sector %

-13.1

Return on Equity vs Industry %

-15.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

1038.8

stock quote shares HZNP – Horizon Therapeutics Public Limited Company Stock Price stock today

news today HZNP – Horizon Therapeutics Public Limited Company stock forecast ,stock prediction 2023 2024 2025

marketwatch HZNP – Horizon Therapeutics Public Limited Company yahoo finance google finance

stock history HZNP – Horizon Therapeutics Public Limited Company invest stock market

stock prices HZNP premarket after hours

ticker HZNP fair value insiders trading

No more stocks to show

AMRN – Amarin Corp ADR

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: AMRN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

GRFS – Grifols, S.A.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: GRFS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y